Document Type: Review Article

Authors
Soneil Guptha, Eteri Tsetskhladze
Chair, 4H-CARE LLC, San Diego, California, United States of America; Vice President (Medical Affairs), Worldwide Clinical Trials, Tbilisi, Georgia

DOI: 10.37821/ruhsjhs.8.1.2023.533 [Downloaded: 0 times], [Page visited: 0 times]

Abstract
Heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure, is a complex entity. It is due to various causes and has heterogeneous presentations and therefore, has evaded evidence compelling for developing standard guidelines for therapeutic intervention. In February 2021, the US Federal Drug Agency approved Sacubitril-Valsartan (angiotensin receptor neprilysin inhibitor-angiotensin receptor blocker: ARNIARB) combination for HFpEF. A past review (Part 1) outlined the experience and management of HFpEF with comments on various clinical trials using other classes of drugs. This second part of the review shall discuss the emerging importance of SGLT-2 inhibitors for HFpEF.

Keywords
Cardiovascular clinical trials, heart failure, heart failure with preserved ejection fraction (HFpEF), SGLT-2 inhibitors.